ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ERNA / earnings
EOCN (34) CMND (47) SXTP (38) ONCO (30) ⌘ Pro Terminal →

Ernexa Therapeutics Inc. (ERNA) Next Earnings Date & Expected ±12.5% Move

$1.95 -1.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.94

Ernexa Therapeutics Inc. (ERNA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ERNA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ERNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Ernexa Therapeutics Inc. (NASDAQ: ERNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.95 (-1.01% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ERNA ranks #705 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ERNA compare to EOCN and CMND in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ERNA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, ERNA leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ERNA?
▼

Per ERNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000748592), Ernexa Therapeutics Inc. generated $26.1M in revenue (+4383.4% YoY), -$14.1M in net income, and -$7.1M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.94 (-0.37%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$50 Bull$2 Base$1 Bear
📬 FREE ERNA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ERNA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY ERNA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$2.21+1.4% Next Q
Q2 (-2Q)
38
Grade E$2.24-11.2% Next Q
Q3 (-1Q)
36
Grade E$1.99-2% Next Q
Current
33
Grade E$1.95-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ERNA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ERNA currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.19) and Max Pain ($2.05) forces dealer call-delta covering toward $49.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ERNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ERNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.24 Expected Swing
$1.71 (-12.5%)Spot $1.95$2.19 (+12.5%)
MODEL EARNINGS SETUP GAUGE

ERNA Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (33/100)Model Risk Weight (67/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$26.1M-$14.1M-$7.1M52%
FY 20242024-12-31$582.0K-$44.5M-$16.2M83.5%
FY 20232023-12-31$68.0K-$21.7M-$20.4M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ERNA)

  • ✓Walkthrough of ERNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ERNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.86%⚡ TESTING RESISTANCE
2026-11-03O $2.11H $2.11L $1.95C $1.95VOL 4.5K
RES: $2.67SUP: $1.55SMA50: $3.19SMA200: $7.07
$27.79$20.76$13.72$6.69$-0.34RES $2.67SUP $1.55$1.952026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ERNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ERNA Butterfly Map → + Track ERNA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +4383.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ERNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ERNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ERNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ERNA)

Health Care Rank #705 of 1015 ⚔️ EOCN vs ERNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ERNA vs. EOCN, CMND, SXTP, ONCO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Ernexa Therapeutics Inc. (ERNA) ranks #705 by composite RQD confidence (33/100, grade E) and #974 by equity capitalization ($3.2M). Within this direct 5-issuer industry benchmark cohort, ERNA leads on earnings valuation at N/A trailing P/E, while ERNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ERNA at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ERNA ACTIVE
Ernexa Therapeutics Inc.
E 33/100 — — -35.0% -1.01% $3.2M Benchmark Subject
EOCN
Eocene Ltd.
E 34/100 — — -35.0% -7.54% $3.2M /eocn-vs-erna →
CMND
Clearmind Medicine Inc.
D 47/100 — — — -1.27% $3.2M /cmnd-vs-erna →
SXTP
60 Degrees Pharmaceuticals Inc.
D- 38/100 — 22.3% -35.0% -3.65% $3.3M /sxtp-vs-erna →
ONCO
Onconetix Inc.
E 30/100 — 77.6% -35.0% -3.24% $3.3M /onco-vs-erna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000748592 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ernexa Therapeutics Inc. (ERNA) reported GAAP revenue of $26.1M (+4383.4% vs. FY2024 revenue of $582.0K , and +38272.4% cumulative change since FY2023) , GAAP net income of -$14.1M, operating cash flow of -$7.0M, and free cash flow of -$7.1M (+56.5% YoY). On the balance sheet, ERNA closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $26.1M -$14.1M -$7.0M -$7.1M $5.8M —
FY2024 (FY) 2024-12-31 $582.0K -$44.5M -$15.8M -$16.2M $5.3M —
FY2023 (FY) 2023-12-31 $68.0K -$21.7M -$20.4M -$20.4M — —

3. ERNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ERNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Ernexa Therapeutics Inc. (NASDAQ: ERNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.95 (-1.01% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ERNA ranks #705 in composite RQD confidence.

How does ERNA compare to EOCN and CMND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ERNA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, ERNA leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ERNA?

Per ERNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000748592), Ernexa Therapeutics Inc. generated $26.1M in revenue (+4383.4% YoY), -$14.1M in net income, and -$7.1M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ERNA trading relative to its 50-day, 200-day, and 52-week technical levels?

ERNA last traded at $1.95 (-1.01% on volume of 9,001 shares), positioning the stock -38.87% below its 50-day simple moving average ($3.19) and -72.42% below its 200-day simple moving average ($7.07). Across its 52-week range of $1.84 to $47.25, ERNA sits at the 0.2% percentile with a 14-day RSI of 34.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.71 to $2.19).

Direct Sub-Reports: ERNA RQD Cockpit ERNA 12M Forecast ERNA Earnings & Move ERNA Dividends & DRIP ERNA Insiders & 13F ERNA Whale Options ERNA Profit Sankey ERNA News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

ERNA — Ernexa Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Ernexa Therapeutics Inc. (ERNA) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.95 (-1.01% 1D, market capitalization $3.2M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Ernexa Therapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The source does not describe its products, customers, or revenue model. Reported revenue is — for FY 2025, $0.6M for FY 2024, and $0.1M for FY 2023, . Its news flow references ERNA-101 and a cell therapy plus immune treatment in animal studies.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ernexa Therapeutics Inc. (ERNA) reported $26.1M in annual revenue (up from $582.0K in FY2024, +4383.4% YoY) and -$14.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($68.0K revenue, -$21.7M net income) through FY2025, ERNA scaled operating cash flow to -$7.0M and free cash flow to -$7.1M, backed by $5.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.84 – $47.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

An investor should note that the absence of mapped dependencies means no ripple effects can be traced from this source.

  • Key Question #1: Can ERNA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $26.1M and free cash flow of -$7.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ERNA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ERNA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ernexa Therapeutics Inc. (ERNA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ERNA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ERNA Bull vs. Bear Conversation Board — What's Your Call at $1.95?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ERNA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ERNA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $2.50 (+26.9%)
📌 Pinned Debate

The stock shows a recent 6.57% price gain and news flow on ERNA-101 animal results and a Flash Talk selection.

The stock shows a recent 6.57% price gain and news flow on ERNA-101 animal results and a Flash Talk selection.. When you look under the hood at ERNA, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $47.25. My 12M target is $2.50.

RetailWhale_TX 🐂 BULL

Both sides have a point here — ERNA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.69 (-14.2%)
Spot @ $1.97

The RQD score of 33 (grade E) is driven by ROIC of -35%, 0% FCF yield, and a whale flow score of 3 out of 20.

Fading this rally in ERNA at $1.97. The RQD score of 33 (grade E) is driven by ROIC of -35%, 0% FCF yield, and a whale flow score of 3 out of 20.. With a beta of 1.0 and the stock sitting at $1.97 (52-wk range $1.84–$47.25), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%